Blauvelt, A.; Rich, P.; Sofen, H.; Lambert, J.; Merola, J. F.; Lebwohl, M.; Scharnitz, T.; Hoyt, K.; Kisa, R. M.; Banerjee, S. Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Scalp, Nail, and Palmoplantar Psoriasis: Subgroup Analyses of the Phase 3 POETYK PSO-1 and PSO-2 Trials. J of Skin 2022, 6, s49.